Author:
Risueño Alberto,See Wendy L.,Bluemmert Iryna,de Botton Stéphane,DiNardo Courtney D.,Fathi Amir T.,Schuh Andre C.,Montesinos Pau,Vyas Paresh,Prebet Thomas,Gandhi Anita,Hasan Maroof
Reference20 articles.
1. E. National Cancer Institute: Surveillance, and End Results Program, Cancer stat facts: Leukemia — Acute myeloid leukemia (AML), 2023. 〈https://seer.cancer.gov/statfacts/html/amyl.html〉.
2. Acute myeloid leukemia-genetic alterations and their clinical prognosis;Lagunas-Rangel;Int J. Hematol. Oncol. Stem Cell Res,2017
3. A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study;Karanes;Leuk. Res,1999
4. International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia;Roboz;J. Clin. Oncol.,2014
5. Acute myeloid leukemia;Dohner;N. Engl. J. Med,2015